T helper (Th) 17 cells have emerged as important mediators in infectious and inflammatory diseases and, recently, in transplant rejection. We analyzed the associations between five common genetic variants in the IL-23/ Th17 signaling pathway, namely in IL17A, IL17F and IL23R genes, and clinical outcome in T cell-depleted allogeneic SCT (allo-SCT). In the multivariate analysis, variants in IL23R and IL17A genes were the most important prognostic factors. Thus, patient GA genotype at rs11209026 in IL23R was associated with improved overall survival (hazard ratio (HR) ¼ 0.48; P ¼ 0.028) and, in donor, with decreased risk of fungal infections (P ¼ 0.05). In contrast, patient TC and CC genotypes at rs8193036 in IL17A gene were associated with increased risk of CMV infection (HR ¼ 3.68; P ¼ 0.011) and patient acute GVHD (HR ¼ 7.08; P ¼ 0.008), respectively. These results suggest that genetic variants in the IL-23/Th17 inflammatory pathway are important prognostic factors for the clinical outcome of allo-SCT. Although validation studies are ultimately required, our results would suggest the potential usefulness of IL-23/Th17 genotyping in donor selection and patient evaluation.
Introduction
The immunogenetic make-up of donors and recipients of allogeneic SCT (allo-SCT) can strongly influence the success or failure of allo-SCT. [1] [2] [3] [4] A link between polymorphic features of non-HLA cytokine-encoding genes and the incidence and severity of post transplant complications in allo-SCT recipients has been recognized, implying that donor-recipient genotyping, extended for immune response loci, may be of prognostic value for transplantation outcome. 5 Much effort has been devoted to the understanding of the role of T helper (Th) cell polarization in the manifestation of post transplant complications. Although Th1/Th2 kinetics and lymphocyte subsets are known to influence transplantation outcome, 6 T cells other than Th1 or Th2 are also likely to have a role in mediating post transplant events. Th17 cells belong to a newly identified T cell lineage in addition to the classic Th1 and Th2 subsets. 7 Differentiation of Th17 is primarily driven by IL-6 and transforming growth factor-b, 8 whereas IL-23 is the foremost determinant for survival and expansion of the Th17 cell lineage. 9 Differentiated cells are characterized by the production of IL-17A (also called IL-17), IL-17F, IL-22 and IL-21; 10 cytokines reported to mediate host responses to pathogens not effectively handled by Th1 or Th2 cells 11, 12 and to have crucial effector functions in inflammatory 13 and autoimmune processes. 14 Although many studies have focused on the pathological aspects of IL-17-producing T cells in inflammation and autoimmunity, the relevance of the Th17 cell subset in the transplantation outcome is beginning to be appreciated. 15 With some exception, 16 Th17 cells, being able to migrate and expand in GVHD target organs, 17 have been associated with GVHD progression in allo-SCT recipients. 18 Similarly, high levels of IL-23/IL-17 positively correlated with rejection in liver transplantation. 19 It appears that an imbalance between Th17 and regulatory T cells (Treg) ultimately associates with the development of transplant rejection. 20, 21 Considering that the role of Th17 cells in protection vs pathology in infectious diseases is also controversial, with protective 11, 22, 23 and detrimental 12, 24, 25 effects being reported, it follows that genetic variants affecting the expression of cytokines of the IL-23/Th17 pathway may have a role in transplantation outcome. We have investigated the association of common genetic variants in genes from the IL-23/Th17 signaling pathway, namely IL17A, IL17F and IL23R, with the incidence of acute GVHD (aGVHD), disease relapse, TRM, infections, infection-free survival (IFS) and OS of patients undergoing T-cell-depleted allo-SCT.
Materials and methods

Study population
A total of 201 patients with hematological malignancies, who underwent T-cell-depleted allo-SCT, and for whom stored donor and patient DNA was available, were included in the study. All transplants were performed at the Hematopoietic Stem Cell Transplant Unit, Ospedale S. Maria della Misericordia, Perugia, Italy, between January 2003 and December 2008. Main patient, disease and transplantation characteristics are summarized in Table 1 . Graft processing and transplantation procedures were performed as previously described. 26 Grafts consisted of immunoselected CD34
þ peripheral blood cells in all cases. Donors were HLA-identical siblings in 66 patients and one haplotype-mismatched family members in 135 patients. Donor-vs-natural killer cell alloreactivity, determined by HLA-C high-resolution molecular typing and killer immunoglobulin-like receptor genotyping, and functional assessment of donor natural killer clonal repertoire in cytotoxicity assays, was sought in each donor-recipient pair. 27 Ideally, CMV-negative donors were avoided for CMV-positive recipients to limit CMV re-activation. No GVHD prophylaxis or G-CSF was administered post transplant. The local ethics committee provided institutional review board approval for this study and informed written consent was obtained from each participant.
Genotyping
Genomic DNA from whole blood samples from patients and donors was isolated before transplant using the QIAamp DNA Mini (Qiagen, Milan, Italy) following the manufacturer's instructions and stored at À20 1C. Five genetic variants spanning the IL17A (rs2275913 and rs8193036), IL17F (rs763780 and rs2397084) and IL23R (rs11209026) genes were selected based on previously published evidence of association in case-control studies. [28] [29] [30] Preference was given to genetic variants presenting minor allele frequencies X5% and located in coding or promoter regions. Allelic variants were genotyped using bidirectional PCR amplification of specific alleles, as previously described. 31, 32 Regarding quality control, each PCR set comprised randomly selected replicates of previously typed samples from the study and two negative controls. Agreement for quality control and duplicates was X99% for all assays. Laboratory personnel were blind to the sample status.
Microbiological and clinical evaluation
Antifungal prophylaxis included liposomal amphotericin-B (1 mg/kg/daily) in high-risk patients and fluconazol (400 mg/daily) in low-risk patients from day À5 until neutropenia ended. Surveillance cultures for fungal growth from stool, urine, nasal and oral washes were performed twice weekly during first 180 days post transplant. Surveillance also included the determination of blood galactomannan (Platelia Aspergillus EIA, Bio-Rad Laboratories, Milan, Italy). In addition, blood, sputum, bronchoalveolar lavage and cultures of samples from infected sites were analyzed when clinical signs and/or symptoms of infection appeared. Positivity of microbiological tests with clinical or instrumental signs of fungal infection was considered indicative of probable/proven infection according to the revised standard criteria, 33 in which case, conventional antifungal treatment was started.
The CMV prophylaxis consisted of ganciclovir (10 mg/ kg/daily) from day À9 to day À2 and foscarnet (90 mg/kg/ daily) from day þ 4 to day þ 20 followed by pre-emptive therapy. According to our standard practice, CMV pp65 antigenemia and immediate early antigen detection by immunofluorescence (Argene Biosoft, Varilhes, France), and real-time PCR (COBAS Amplicor CMV Monitor test, Roche, Branchburg, NJ, USA) assays were routinely performed twice weekly during first 180 days post transplant in CMV-seropositive recipients. 34 If any clinical signs or symptoms were present associated with a positive culture, positive pp65 antigenemia and/or the presence of 410 000 CMV DNA copies per 100 000 mononuclear cells, CMV infection was diagnosed. 
Data analysis
Consistency of genotype frequencies with the HardyWeinberg equilibrium was tested using a w 2 test on a contingency table of observed vs predicted genotype frequencies. Seven endpoints were considered in the analyses: aGVHD grades II-IV, relapse, TRM, fungal infections, CMV infection, IFS and OS, with the reference date being June 1, 2009. All end points except IFS and OS were analyzed using the Gray test. 35 Cumulative incidences were computed using the cmprsk package for R 2.9.0 software. 36 The competing events were defined as follows: in the case of aGVHD and relapse, the competing event was death; for TRM, the competing event was relapse; for infections, the competing events were relapse and death. The IFS and OS values were defined as the time from first day of treatment to death due to any infection or death due to any cause, respectively. The IFS and OS values were obtained by the Kaplan-Meier method and compared using the log-rank test. Variables included in the univariate analyses were: donor and patient genotype for each variant, patient age (younger vs older than the median), patient gender, relation donor-patient gender (donor female into recipient male vs others), disease stage (advanced vs early), transplant matching (HLA-identical sibling vs one HLA haplotype-mismatched family member), CMV serology of donors and patients (donor CMV-negative and patient CMV-negative vs others), conditioning regimen (with TBI vs absence of TBI) and killer immunoglobulin-like receptor genotype (matched vs mismatched). The GVHD condition was also considered in the univariate analysis as a time-dependent covariate regarding infection outcomes. All prognostic variables in the univariate analysis with a P-value p0.15 were included in the multivariate analysis. Multivariate analysis was performed using the subdistribution regression model of Fine and Gray 37 using the cmprsk package for R 2.9.0 software, 36 with the exception of IFS and OS, which was performed by Cox regression with backward method and Wald statistic using the SPSS 16.0 software (SPSS, Chicago, IL, USA). The P-values reported remained significant with the application of traditional Bonferroni corrections for multiple comparisons.
Results
Genotype frequencies
Five genetic variants in IL17A (rs8193036 and rs2275913), IL17F (rs2397084 and rs763780) and IL23R (rs11209026) genes were analyzed in 201 T cell-depleted allo-SCT donor-recipient pairs. Allele and genotype frequencies for each variant studied were similar to those observed in the National Center for Biotechnology Information (NCBI) database and comparable between donors and patients (data not shown). Genotype frequencies in both patients and donors did not deviate from those predicted by the Hardy-Weinberg equilibrium (P40.05). Variants rs8193036 and rs2275913 in IL17A and variants rs2397084 and rs763780 in IL17F did not present significant linkage disequilibrium (P40.05).
The univariate analysis of associations between genetic variants in IL17A, IL17F and IL23R, and transplant outcomes is presented in Tables 2 and 3 , whereas the multivariate analysis of associations between genetic and/or clinical risk factors and transplant outcomes is shown in Table 4 .
Acute GVHD A total of 12 (6%) of the 201 patients, included in the study, developed aGVHD. The only clinical risk factor associated with aGVHD grades II-IV in the univariate analysis was to be transplanted in advanced phase of disease (10 vs 4% at 100 days; P ¼ 0.03). Two genetic variants, one in both donor and patient IL17F gene (rs763780) and the other in patient IL17A gene (rs8193036) were associated with aGVHD grades II-IV ( Table 2 ). Cumulative incidence for aGVHD at 100 days of patient IL17A rs8193036 was: TT 5%, TC 2% and CC 20% (P ¼ 0.04), whereas for both donor and patient IL17F rs763780 was: TT 4% and TC 23% (P ¼ 0.009). Donor IL17A rs8193036 also displayed a trend for increased aGVHD (cumulative incidence at 100 days: TT 3%, TC 9% and CC 20%; P ¼ 0.06). However, in the multivariate analysis, only donor rs763780 TC genotype (HR ¼ 9.30; 95% cumulative incidence (CI) ¼ 2.1-40.6; P ¼ 0.003), patient rs8193036 CC genotype (HR ¼ 7.08; 95% CI ¼ 1.7-29.9; P ¼ 0.008) and advanced phase of disease (HR ¼ 4.82; 95% CI ¼ 1.5-16.0; P ¼ 0.010) remained significant (Table 4) . Although the low incidence of aGVHD cases, an intrinsic feature of our transplantation procedure, 34 precludes the proper appreciation of our findings, the above associations are consistent with the observation that both IL-17 and Th17 cells are involved in GVHD pathogenesis.
17,18
CMV infection A total of 20 (10%) of 201 patients had post transplant CMV infection. Clinical risk factors associated with a trend for CMV infection in the univariate analysis were to be female (10 vs 6% at 180 days; P ¼ 0.05) and to have a gender pairing in the transplant other than donor female/ patient male (10 vs 4% at 180 days; P ¼ 0.09). Two genetic variants, one in both patient and donor IL17A gene (rs8193036) and the other in donor IL23R (rs11209026) were associated with increased risk of CMV infection (Table 3) . Cumulative incidence of patient and donor IL17A rs8193036 at 180 days was: TT 4%, TC 19% and CC 7% (P ¼ 0.01), and TT 9%, TC 3% and CC 30% (P ¼ 0.02), respectively. Cumulative incidence of IL23R rs11209026 at 180 days was: GG 6% and GA 21% (P ¼ 0.01). In the multivariate analysis, patient rs8193036 TC genotype (HR ¼ 3.68; 95% CI ¼ 1.3-10.1; P ¼ 0.011) and donor rs11209026 GA genotype (HR ¼ 2.78, 95% CI ¼ 1.0-7.6, P ¼ 0.046) remained significant (Table 4) . Furthermore, an additional genetic variant, patient IL17A rs2275913, although with a trend for decreased risk of CMV infection (cumulative incidence at 180 days: GG 11%, GA 3% and AA 14%; P ¼ 0.09), did not confirm an association in the multivariate analysis. 
Fungal infections
the univariate analysis were to receive an HLA-haplotype mismatched transplant (16 vs 5% at 180 days; P ¼ 0.03), to develop aGVHD (17 vs 11% at 180 days; P ¼ 0.11) and to be conditioned with TBI (13 vs 7% at 180 days; P ¼ 0.13). Although a trend toward protection was observed for patient IL17A rs2275913 (cumulative incidence at 180 days: GG 15%, GA 8% and AA 16%; P ¼ 0.15), no significant associations with fungal infections were found with the variants previously correlated with aGVHD, IL17A rs8193036 and IL17F rs763780. Interestingly, however, donor IL23R rs11209026 was associated with decreased risk of fungal infections (Table 3) . Cumulative incidence for fungal infections of donor IL23R rs11209026 at 180 days was: GG 14% and GA 0% (P ¼ 0.05). In the multivariate analysis, receiving an HLA-haplotype mismatched transplant was the only variable to remain significant (HR ¼ 3.43; 95% CI ¼ 1.2-10.0; P ¼ 0.024) ( Table 4) , as no hazard ratio was computed for donor IL23R rs11209026 due to lack of fungal infection events harboring the genetic variant.
Infection-free survival
Infections were directly responsible for 33 of 118 (28%) deaths in the whole period of follow-up. Median follow-up time was 31 months (range ¼ 5-77 months) for the surviving patients and 6 months (range ¼ 1-14 months) for the patients who died from any infection. In the univariate analysis, the only clinical risk factor associated with worse IFS was to be transplanted at advanced phase of disease (80 vs 92%; P ¼ 0.031). We found that the variant increasing the risk of CMV infection, patient IL17A rs8193036, also worsened IFS (TT 87%, TC 69% and CC 100% long-term survivors; P ¼ 0.005; Table 3 ). In contrast, donor IL17F rs2397084 improved IFS (TT 81% and TC 95% long-term survivors; P ¼ 0.032; Table 3 ). In the multivariate analysis, patient IL17A rs8193036 TC genotype (HR ¼ 2.76; 95% CI ¼ 1.4-5.5; P ¼ 0.004) and donor IL17F rs2397084 TC genotype (HR ¼ 0.23; 95% CI ¼ 0.06-1.0; P ¼ 0.048) remained significant (Table 4) .
Relapse or progression A total of 52 (26%) of 201 patients relapsed or progressed after transplantation, the median time to progression being 9 months (range ¼ 2-57 months). In the univariate analysis, clinical risk factors associated with a trend for relapse were to be male (21 vs 14% at 1 year; P ¼ 0.04) and transplanted in advanced phase of disease (26 vs 14% at 1 year; P ¼ 0.07). We found that patient IL17A rs8193036 and donor IL23R rs11209026 were associated with protection from disease relapse ( Table 2) . Cumulative incidence for relapse at 1 year of patient IL17A rs8193036 was: TT 22%, TC 4% and CC 20% (P ¼ 0.001), whereas of donor IL23R rs11209026 was: GG 19% and GA 8% (P ¼ 0.05). In addition, donor IL17A rs2275913 variant also protected from disease relapse (cumulative incidence at 1 year: GG 21%, GA 18% and AA 4%; P ¼ 0.07 (Table 4) .
TRM
A total of 33 (16%) patients died from transplant-related causes. Clinical risk factors in the univariate analysis associated with TRM were to receive an HLA haplotypemismatched transplant (19 vs 7% at 1 year; P ¼ 0.05) and transplantation in advanced phase of disease (23 vs 12% at 1 year; P ¼ 0.05). Patient IL23R rs11209026 was apparently associated with reduced TRM. Cumulative incidence for TRM of patient IL23R rs11209026 at 1 year was: GG 17% and GA 4% (P ¼ 0.001). Donor rs8193036 IL17A variant demonstrated instead a trend for increased TRM (cumulative incidence at 1 year: TT 13%, TC 16% and CC 40%; P ¼ 0.14). In the multivariate analysis, however, only HLA haplotype mismatching (HR ¼ 2.70; 95% CI ¼ 1.1-6.6; P ¼ 0.028) remained significant (Table 4) .
OS
A total of 118 (59%) patients died after transplant, leaving 83 (41%) long-term survivors. Median follow-up time was 31 months (range ¼ 5-77 months) for the surviving patients and 6 months (range ¼ 1-57 months) for the patients who died. Clinical risk factors associated or with a trend towards a worse OS were to receive an HLA haplotypemismatched transplant (35 vs 55%; P ¼ 0.02) and to be transplanted in advanced phase of disease (37 vs 50%; P ¼ 0.12). We found that the only genetic variant associated with increased OS was patient IL23R rs11209026 (GG 38% and GA 63% long-term survivors; P ¼ 0.03; Table 2 ; Figure 1 (Table 4) .
Discussion
Genetic variants in cytokine genes can influence immune responses and inflammation, thereby affecting the outcome of hematopoietic SCT. Our results provide evidence for strong associations between common genetic variants in the IL-23/Th17 signaling pathway and the clinical outcome after T cell-depleted allo-SCT. It has already been shown that the IL23R rs11209026 variant confers strong protection not only against inflammatory bowel disease, 38 but also against GVHD in recipients of hematopoietic cells from HLA-identical donors. 28 We found that the rs11209026 variant in donor was associated with decreased risk of fungal infections and, IL-23/Th17 genetic variants in transplantation A Carvalho et al in patient, with improved OS, a finding consistent with the protective effects of IL-23 signaling attenuation in experimental aspergillosis. 25 The fact that donor rs11209026 also increased the risk of CMV infection, while consistent with the enhancing role of IL-23 of antiviral immunity, 39 indicates that fungal more than CMV infection may impact on OS in our cohort of patients. Although the variant could arguably influence OS by modifying the incidence of disease relapse or GVHD, a beneficial effect on relapse was only demonstrated in the univariate analysis and no effect on GVHD was found whatsoever.
Although Th17 cells and their cytokines are involved in the balance between rejection and tolerance in transplantation, 15 no studies assessing the correlation between IL-17 gene variants and outcome have been carried out in transplantation. Of the genetic variants analyzed, patient IL17A rs8193036, specifically the CC genotype, was associated with increased risk of aGVHD, despite the fact that the low incidence of aGVHD in our transplantation setting may affect the statistical strength of our finding.
Interestingly this variant has been previously linked with the development of pediatric asthma, an autoimmune condition in which increased levels of IL-17 are pathogenic. 30 Although not directly proved in this study, our result probably reflects the effects of altered transcription factor binding to the IL17A promoter leading to genotype-specific variations in cytokine production. We observed that donor IL17F rs763780 was also associated with increased risk of aGVHD. This variant has been reported to protect from asthma, an effect mediated through the inability of the uncommon variant form to activate cytokine production on target cells, thus behaving as a functional antagonist of proinflammatory wild-type IL-17F. 29 Should this occur in our setting, it would point to IL-17F as a cytokine contributing to transplantation tolerance. In this regard, it is of interest that donor IL17F rs2397084 also improved IFS in allo-SCT recipients; an interesting finding that needs nevertheless confirmation and further insights in experimental models of allo-SCT and infections.
Patient IL17A rs8193036 was also shown to promote an increased risk of CMV infection, arguing for an adverse role of IL-17A in infection, at least under certain circumstances. It has indeed recently been shown that IL-17A, by activating antiapoptotic signaling pathways, enhances survival of virus-infected cells and contributes to viral persistence. 24 Thus, the promotion of CMV infection and aGVHD will explain the detrimental effect of IL17A rs8193036 on IFS.
Further adding to the general concept of different susceptibility phenotypes depending on the immunogenetic background of donors and recipients, our results point to the importance of genetic variants in the IL-23/Th17 signaling pathway for the clinical outcome after allo-SCT. Much remains to be done to fully appreciate the role of the IL-23/Th17 pathway in transplantation, including the relative impact of these genetic variants on host radio-resistant vs donor hematopoietic cellular pathways. In addition, the finding that the genetic IL17A variants, rs8193036 and rs2275913, protect from disease relapse independently of the underlying hematological malignancy remains to be fully elucidated. It is noteworthy, however, that a protective role for endogenous IL-17 on tumor immunity has been demonstrated, as IL-17-deficient mice were shown to have enhanced tumor growth and metastasis. 40 Despite the need for validation studies in independent data sets, the absence of extensive coverage of genetic variability in Th17-associated genes and the combined analysis of HLA-matched and -mismatched donor-recipient pairs that may hamper the precise appreciation of some associations, these results point to the intricacies between the immune state and clinical outcome in the setting of hematopoietic transplantation. Our results suggest the usefulness of Th17 genotypes in the standard evaluation of donors and patients under consideration for allo-SCT, at least in T cell-depleted transplantation. As an increasing number of reports have been demonstrating the association of various genetic variants with the clinical outcome after allo-SCT, further studies comprising all known significant variants in a context of donor-patient immunogenetic profiling, together with studies elucidating the functional impact of the variants, are warranted.
